Apalutamide in prostate cancer: indication of significant added benefit

IQWiG

2 May 2019 - Study shows significant slowing of symptomatic progression.

Do adult men with non-metastatic castration-resistant prostate cancer, who are at high risk of developing metastases, benefit from treatment with apalutamide - or are they better off just continuing their conventional androgen deprivation therapy? This question has been examined by IQWiG in an early benefit assessment. 

Analysis of the data from the ongoing randomised controlled trial SPARTAN revealed evidence of significant added value of the new drug.

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder